TNeuroPharma is developing the T-Track™ Biomarker technology to identify Alzheimer’s disease in its earliest stages by targeting dysfunctional T cells, enabling early diagnosis before significant brain damage occurs. This approach allows pharmaceutical companies to conduct more effective clinical trials and monitor drug efficacy in real time, potentially reducing development costs and accelerating breakthroughs in treatment.
Funding
$290K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting Alzheimer's disease are limited in their ability to identify the condition in its earliest stages, often detecting it only after significant brain damage has already occurred. This late detection hinders the development of effective treatments and preventative measures.
Solution
T-Neuro Pharma is developing the T-Track™ Biomarker technology, a novel approach to identify Alzheimer's disease in its earliest stages by targeting dysfunctional T cells. This technology enables the detection of Alzheimer's before substantial brain damage occurs, providing a crucial advantage for early intervention and treatment. The T-Track™ Biomarker allows pharmaceutical companies to conduct more effective clinical trials by identifying and monitoring confirmed Alzheimer's patients. Furthermore, it enables real-time monitoring of drug efficacy, potentially reducing drug development costs and accelerating breakthroughs in Alzheimer's treatment.
Target Audience
The primary customers are pharmaceutical companies conducting clinical trials for Alzheimer's disease treatments, as well as researchers and clinicians focused on early detection and intervention.
Features
- Targets dysfunctional T cells, which are implicated in the early stages of Alzheimer's disease.
- Enables early diagnosis of Alzheimer's, before significant brain damage occurs.
- Facilitates more effective clinical trials by identifying confirmed AD patients.
- Allows real-time monitoring of drug efficacy during clinical trials.
- Offers a less-invasive and more cost-effective technology for broader screening.
- Evaluates biomarkers in blood samples across the Alzheimer's continuum.